As three biotechs head to Wall Street, a battered sector braces for a pullback

[cafead]

via Amylyx, CinCor and Vigil raised about $480 million combined, a hopeful sign for continued investor interest in biotech IPOs. But industry analysts expect fewer and smaller offerings in 2022

article source